Global Immunotherapy
Market Report
2025
Immunotherapy Market Report 2025 (Global Edition)
Delivery Includes:- Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Immunotherapy Market Report 2024.
Global Immunotherapy Market Report 2024 Market Size Split by Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccines, Others), by Disease (Cancer, Autoimmune Diseases, Infectious Diseases, Other...
According to Cognitive Market Research, The Immunotherapy Market will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.
North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031.
The Europe region is the fastest growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future.
Asia Pacific accounted for a market share of over XX% of the global revenue with a market size of USD XX million.
Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
The Immunotherapy Market held the highest market revenue share in 2024.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Market Size | 121212 |
| Country Market Size | 121212 |
| North Americ Market Size | 121212 |
| Europe Market Size | 121212 |
| Asia Pacific Market Size | 121212 |
| South America Market Size | 121212 |
| Middle East and Africa Market Size | 121212 |
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
| |
| Market Split by Drug Type |
|
| Market Split by Disease |
|
| Market Split by End User |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Report scope is customizable as we have a huge database of Immunotherapy industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Immunotherapy Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Immunotherapy Market Report Description
Introduction of The Immunotherapy Market
Immunotherapy is a type of medical treatment that stimulates the body's immune system to fight diseases, including cancer. Immunotherapy drugs are designed to enhance or modify the immune system's response to target and eliminate abnormal cells. Immunotherapy is used to treat various cancers including melanoma, Non-small Cell Lung Cancer (NSCLC), and Head and Neck Squamous Cell Carcinoma (HNSCC). It targets the PD-1 protein in immune cells, allowing them to attack cancer cells more effectively. Immunotherapy is employed in the treatment of certain types of lymphoma and leukemia. It involves modifying a patient's T cells to express a Chimeric Antigen Receptor (CAR) that targets cancer cells.
The market for immunotherapy medications is expanding mostly due to rising cancer incidence and rising healthcare professionals' understanding of the disease. Globally, the number of cancer patients is increasing, and the World Health Organization (WHO) projects that within the next two decades, there will be a 70% increase in the number of cancer patients. The expanding number of cancer patients has led to a major increase in the need for innovative and effective treatment alternatives in recent years. One of the most promising forms of cancer treatment is immunotherapy, which works by boosting a patient's immune system to combat cancer cells and enable the patient to have a positive prognosis. On the other hand, In recent years, there has been a significant growth in the knowledge of patients and healthcare professionals about the potential advantages of immunotherapy medications and their efficacy in healing cancer. Because immunotherapy is less toxic and has the potential to induce short-term remission, it is a better treatment than conventional methods like chemotherapy. The use of immunotherapy medications as a cancer patient's treatment choice is expanding as a result of healthcare professionals' rising understanding of the advantages of these medications.
Immunotherapy Market Size
Market Dynamics of The Immunotherapy Market
Key Drivers for The Immunotherapy Market
- The rising prevalence of Cancer in Drugs for immunotherapy fuel the Market for Immunotherapy Market
The drugs for the immunotherapy market are being driven by the rising prevalence of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. Factors like unhealthy lifestyle choices contribute to the rise in cancer cases, creating a substantial market for immunotherapy treatments aimed at combating this growing health concern.
For instance, in October 2022, Macmillan Cancer Support, the largest UK-based healthcare charity organization, estimated that there will be 3.5 million people with cancer by 2025, 4 million by 2030, and 5.3 million by 2040. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. The rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving the drugs for immunotherapy market growth.
Source:( https://www.etas.com/en/company/press-releases-etas-to-unveil-pantaris-a-cloud-based-integration-platform-for-development-of-connected-vehicle-systems-at-ces-2023.php)
Hence, the increasing prevalence of cancer is a significant driving force behind the growth of the immunotherapy market. Factors such as obesity, smoking, alcohol consumption, and poor dietary habits contribute to the rise in cancer cases globally, propelling the demand for immunotherapy drugs.
- Growing Healthcare Spending Fuels Demand for Immunotherapy Market
The market for immunotherapy medications is expected to rise at a faster rate due to rising healthcare costs. The total amount of money spent on medical supplies and services in a certain area or nation during a given time frame is referred to as healthcare expenditure. This sum includes payments for doctor visits, hospital stays, operations, diagnostic tests, and treatments. Individuals, insurance companies, government organizations, and healthcare providers all contribute financial resources to the cost of healthcare to pay for the medications used in immunotherapy and other treatments.
For instance, in May 2023, The Office for National Statistics, a UK-based government department, The UK had an increase in healthcare spending of 9.4% in nominal terms and 9.7% in real terms. In the UK, total healthcare spending in 2021 was $367.25 billion (£280.7 billion), pharmaceutical spending was $51.84 billion (£39.6 billion), and preventative care spending more than doubled from the previous year to $45.93 billion (£35.1 billion). Therefore, the increasing healthcare expenditure is driving the growth of the drugs for the immunotherapy market.
Source:(https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthcaresystem/bulletins/ukhealthaccounts/2021)
Thus the escalating healthcare expenditure worldwide is fueling the demand for immunotherapy medications. As healthcare costs continue to rise, individuals, insurance companies, government bodies, and healthcare providers allocate substantial financial resources to cover medical expenses, including immunotherapy treatments, driving the market growth.
Restraint Factor for The Immunotherapy Market
- The high cost of drugs for the immunotherapy market restrains market growth.
The market for immunotherapy medications is being restrained by the high expense of these treatments, which makes the treatment less accessible to patients. The huge investment expenditures in research and development and the fact that immunotherapy medications are customized for each patient make them pricey.
For instance, Novartis’ Kymriah and Gilead Sciences’ Yescarta are two immunotherapy treatments that cost between $373,000 and $475,000 per patient, depending on the type of cancer. The Yervoy (ipilimumab) drug from Bristol-Myers Squibb, for the treatment of melanoma, a type of skin cancer, costs $120,000 per course of treatment. The high cost of immunotherapy drugs makes them unaffordable, thereby affecting the drugs for immunotherapy market growth.
Source:(https://news.bms.com/news/details/2011/FDA-Approves-YERVOY-ipilimumab-for-the-Treatment-of-Patients-with-Newly-Diagnosed-or-Previously-Treated-Unresectable-or-Metastatic-Melanoma-the-Deadliest-Form-of-Skin-Cancer/default.aspx)
Despite its potential, the high cost of immunotherapy drugs poses a significant barrier to market expansion. The substantial investment in research and development, coupled with the personalized nature of immunotherapy treatments, results in expensive therapies, limiting access for many patients and restraining market growth.
How did COVID-19 impact The Immunotherapy Market
The COVID-19 pandemic has had both beneficial and bad effects on the market for immunotherapy medications. One side of the debate is the reallocation of resources by several pharmaceutical firms towards the development of immunotherapy medications that demonstrate action against the COVID-19 virus. The COVID-19 pandemic has significantly increased the need for immunotherapy medications that strengthen the immune system. Numerous governmental agencies and pharmaceutical firms have stepped up their efforts to hasten the creation of diverse immunotherapy medications for a range of illnesses. This has encouraged market expansion. Nonetheless, the COVID-19 pandemic has decreased the need for immunotherapy therapies since attention has been focused on meeting the requirements of COVID-19 patients, which has hindered market expansion and decreased the need for immunotherapy medications. Likewise, the market for immunotherapy medications has been influenced by the COVID-19 epidemic in two ways. Likewise, it is projected that the industry will increase strongly throughout the projected timeframe. decreased the need for immunotherapy medications and hindered the market's expansion, as per an official source's sales figures for 2020.
For instance, In May 2020, VinsBioproducts Ltd. collaborated with the University of Hyderabad and the CSIR Center for Cellular and Molecular Biology, in India to develop an immunotherapy treatment for COVID-19.
Source:(https://www.ccmb.res.in/presscovrg/press_clips_12_04_2020.pdf)
Opportunities for The Immunotherapy Market
- New Developments of immunotherapy drugs in the Market represent a significant opportunity for the automotive industry.
Large players in the immunotherapy medicine industry are concentrating on developing novel items, like pembrolizumab-containing Keytruda, to offer dependable services to clients. For adult patients, immunotherapy using a targeted treatment medication known as an immune checkpoint inhibitor is provided by Keytruda (pembrolizumab).
For Instance, In January 2023, Merck & Co., Inc., a US-based pharmaceutical company, launched Keytruda (pembrolizumab), which was approved by the Food and Drug Administration, a US-based federal agency. Keytruda (pembrolizumab) immunotherapy is used to treat various types of cancer by working with the immune system to help fight cancer cells. KEYTRUDA (pembrolizumab) is approved as an adjuvant treatment for non-small cell lung cancer (NSCLC). This is a significant development in the field of cancer treatment, and it is expected to have a positive impact on the healthcare industry.
Source:(https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-non-small-cell-lung-cancer)
Thus, the factors stated above, such as a rising cancer burden, product launches, and the number of immunotherapy trials in cancer treatment, are likely to grow over the projection period.
We have various report editions of Immunotherapy Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape: The Immunotherapy Market
Key competitors in the Immunotherapy industry compete fiercely with one another. To get a competitive advantage, manufacturers are concentrating on developing innovative products, growing their distribution networks. In the market, strategic alliances, joint ventures, and mergers and acquisitions are also evident.
For instance, Pfizer Inc. Acquired Trillium Therapeutics in November 2021, Pfizer Inc., a US-based Pharmaceutical industry company, acquired Trillium Therapeutics for $2.22 billion. With this acquisition, Pfizer Inc. aims to expand its oncology portfolio with the addition of next-generation, investigational immuno-therapeutics for hematological malignancies. Trillium Therapeutics is a Canada-based Biotech company that provides drugs for immunotherapy.
Source:(https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-trillium-therapeutics)
Top Companies Market Share in Immunotherapy Industry: (In no particular order of Rank)
- Hoffmann-La Roche AG
- GlaxoSmithKline
- AbbVie
- Inc.
- Amgen
- Inc.
- Merck & Co.
- Inc.
- Bristol-Myers Squibb
- Novartis International AG
- Eli Lilly and Company
- Johnson & Johnson
- AstraZeneca plc
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Regional Analysis of The Immunotherapy Market
Which Region Will Dominate the Market in 2024?
According to Cognitive Research, the North America region dominated the market and accounted for the highest revenue of XX% in 2024 and it is projected that it will grow at a CAGR of XX% in the future. Due to due to rising immunotherapeutic product approval in this region. Advanced solutions are in high demand due to the increasing prevalence of cancer and the increased use of advanced cancer therapy. Growth in the area is expected to be aided by the launch and regulatory approval of novel immunotherapy drugs as well as advantageous payment practices. Personalized medicine and next-generation sequencing technology advancements, a strong healthcare research framework, and increased government funding and support for research and development are further factors driving growth in the regional industry. The segment is being driven by an increase in cancer cases as well as the introduction of cancer immunotherapy. Cancer is spreading throughout the world, and so the need for immunotherapy is predicted to rise, as immunotherapy has the potential to be utilized to treat all types of cancer. Immunotherapy enhances the immune system's ability to identify, target, and destroy cancer cells. For instance, according to the American Cancer Society data published in 2023, in the United States 2023, there were 297,790 women and 2,800 men diagnosed with invasive breast cancer, with an additional 55,720 cases of ductal carcinoma in situ (DCIS) detected in women.
Source:(https://www.breastcancer.org/facts-statistics)
For instance, in December 2020, MacroGenics, Inc. obtained FDA approval for MARGENZA to be used in conjunction with chemotherapy to treat adult patients with metastatic HER2-positive breast cancer who have undergone pre-treatment. An increase in product approvals is expected to generate a significant surge in market penetration of approved drugs. In addition, an increasing number of research and development activities conducted by regional market players are expected to lead to novel product launches that are FDA-approved. BLENREP (belantamab mafodotin-blmf), a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior treatments, including an anti-CD38 monoclonal antibody, was approved by the U.S. Food and Drug Administration in August 2020. Therefore, growing research and development activities, product approvals, and rising burden of chronic diseases are also expected to drive market growth.
Source:(http://ir.macrogenics.com/news-releases/news-release-details/margenza-now-approved)
Which Region Is Expanding at The Fastest CAGR?
Europe is expected to show a steady rise in the Immunotherapy Market due to increasing number of product approvals by various European bodies. The expansion may be attributed to three factors: the availability of cutting-edge technology, the establishment of advantageous payment rules, and the growing need for safer cancer treatments. Large countries like France, Germany, and the UK make major contributions to the growth of regional markets. The market for immunotherapy medications is being driven by rising incidence of autoimmune, infectious, and cancerous disorders in Europe.
For instance, in June 2021 PD-1 inhibitor Libtayo (cemiplimab) from Sanofi and Regeneron has received approval from European Commission (EC) for treatment of people with locally advanced or metastatic Basal Cell Carcinoma (BCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI). The first immunotherapy recommended for individuals with advanced basal cell carcinoma is Libtayo (cemiplimab), which has been approved by the European Commission. Moreover, the surge in number of approved immunotherapeutic drugs in Europe is expected to drive market growth.
Source:(https://www.sanofi.com/en/media-room/press-releases/2021/2021-06-25-05-15-26-2252997)
The current report Scope analyzes Immunotherapy Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Immunotherapy Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Immunotherapy Market Analysis
Global Immunotherapy Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Immunotherapy Industry growth. Immunotherapy market has been segmented with the help of its Drug Type, Disease End User, and others. Immunotherapy market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Segment Performance in The Immunotherapy Market
Drug Segment Analysis
Based on drug types, the industry has been further divided into monoclonal antibodies, immunomodulators, and vaccines. The monoclonal antibodies segment accounted for the largest share of XX% CAGR in 2024 owing to increased R&D in therapeutic monoclonal antibodies coupled with supportive government initiatives. Due to their precise targeting, low side effects, adaptability in combination treatments, reliable production, patent protection, and significant clinical success, which is fueled by continuous research investment, monoclonal antibodies dominate the immunotherapy industry.
For instance, in May 2022, the U.S. FDA accepted the supplemental Biologics License Application for priority review of Dupixent (dupilumab) indicated for treating prurigo nodularis. The vaccines segment is expected to register the fastest CAGR during the forecast period.
Source:(https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-sbla-accepted-fda-priority-review-0#:~:text=(NASDAQ%3A%20REGN)%20and%20Sanofi,years%20with%20inadequately%20controlled%20chronic)
Immunotherapy Market Share (%) by Drug Type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Immunotherapy Industry. Request a Free Sample PDF!
Disease Segment Analysis
The cancer segment accounted for the largest revenue share in 2024. The global increase in cancer cases and the trend of substituting chemotherapy with other treatments due to adverse effects are the main factors propelling this segment's revenue rise. The market is being positively influenced by several major aspects, one of which is the increased occurrence of cancer due to aging populations, changes in lifestyle, and environmental factors. Additionally, the market for immunotherapy medications is being stimulated by people's increasing knowledge of the advantages of early cancer detection and treatment. Immunotherapy provides focused therapies that can recognize and target certain cancer cells, limiting harm to healthy tissue, increasing efficacy, and lowering adverse effects. In addition, ongoing funding for cancer research, including the creation of immunotherapies, is provided by governmental agencies, the commercial sector, and charitable groups. This is creating a positive market outlook. Moreover, growing collaborations among pharmaceutical firms, academic institutions, and medical providers are hastening the advancement and availability of cancer immunotherapies.
For instance, in Feb 2024 the World Health Organization (WHO)’s cancer agency, the International Agency for Research on Cancer (IARC), released the latest estimates of the global burden of cancer. WHO also published survey results from 115 countries, showing a majority of countries do not adequately finance priority cancer and palliative care services, as part of universal health coverage (UHC). In 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. The estimated number of people who were alive within 5 years following a cancer diagnosis was 53.5 million. About 1 in 5 people develop cancer in their lifetime, approximately 1 in 9 men and 1 in 12 women die from the disease.
Source:(https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services)
One sort of cancer treatment is immunotherapy, which makes use of molecules produced by the body or in a lab to strengthen the immune system and assist the body in locating and eliminating cancer cells. There is an increased need for efficient therapies, such as immunotherapy medications, owing to the incidence of cancer. Immunotherapies come in various forms and are used to treat cancer. A few examples of are few examples of immunotherapies include immune checkpoint inhibitors, T-cell cell therapy, cancer vaccines, and immune system modulators. Numerous cancer subtypes and their advanced stage are treated with these medicines including Rituxan, Yervoy, Adcetris, and Zevalin.
Immunotherapy Market Share (%) by Disease in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Immunotherapy End User Segment Analysis
End User Segment Analysis
Hospitals hold the largest market share Hospital segment dominated the immunotherapy market as a multidisciplinary team of professionals, comprising nurses, pharmacists, immunologists, and oncologists, works in hospitals. By facilitating a cooperative approach to patient care, these integrated teams guarantee the proper administration and oversight of immunotherapies. Furthermore, they have cutting-edge medical technology and apparatus installed. The application of cutting-edge immunotherapies is made possible by this access. In addition, partnerships with pharmaceutical firms provide hospitals with first access to novel immunotherapy medications and technology. These collaborations improve hospitals' capacity to provide state-of-the-art treatment alternatives. They also understand reimbursement policies better and have developed contacts with insurance companies. Furthermore, a large number of hospitals actively contribute to the development of immunotherapy by their participation in clinical studies and research partnerships.
For instance, according to the National Cancer Institute article published in April 2023, in the U.S. 25% of patients died in a hospital, with 62% hospitalized at least once in the last month of life for the cancer treatments.
Source:(https://www.cancer.gov/about-cancer/advanced-cancer/caregivers/planning/last-days-hp-pdq)
Thus rising incidence of cancer disease, increased treatment rates, higher awareness and diagnosis, and a large number of hospitals offering immunotherapies are contributing to an increase in the number of patients treated. To treat cancer, hospitals are adopting immunotherapies.
- Hospitals
- Clinics
- Others
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
With the help of the above study about the Immunotherapy Market, it can be concluded that the market for Immunotherapy worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.
Frequently Asked Questions
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Immunotherapy Market
In September 2023, NextCure announced the initiation of a Phase I/II trial (NCT03665285) to evaluate the safety and tolerability of NC318 as a potential treatment for advanced or metastatic solid tumors. The trial includes assessments for conditions such as head and neck squamous cell carcinoma, non-small cell lung cancer, and ovarian cancer.
Source:(https://ir.nextcure.com/news-releases/news-release-details/phase-2-study-anti-siglec-15-antibody-nc318-combination)
In January 2023, BioNTech SE signed a Memorandum of Understanding ("MoU") with the U.K. government to expedite clinical trials for personalized mRNA immunotherapies. The goal is to offer personalized cancer therapies to as many as 10,000 patients by the conclusion of 2030, whether in clinical trials or as approved treatments, for the benefit of patients.
Source:(https://investors.biontech.de/news-releases/news-release-details/biontech-announces-strategic-partnership-uk-government-provide)
In 2023, AstraZeneca obtained European Union approval for the tablet formulation of Calquence (acalabrutinib) to treat Chronic Lymphocytic Leukaemia (CLL) in adults. This regulatory approval strengthens AstraZeneca’s market position, expanding treatment options and supporting revenue growth in the field of CLL therapy for adult patients.
Source:(https://www.astrazeneca.com/media-centre/press-releases/2023/calquence-tablet-formulation-approved-in-the-eu-for-patients-with-chronic-lymphocytic-leukaemia.html)
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
Immunotherapy Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Drug Type | Monoclonal Antibodies, Immunomodulators, Vaccines, Others |
| Disease | Cancer, Autoimmune Diseases, Infectious Diseases, Others |
| End User | Hospitals, Clinics, Others |
| List of Competitors | Hoffmann-La Roche AG, GlaxoSmithKline, AbbVie, Inc., Amgen, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Novartis International AG, Eli Lilly and Company, Johnson & Johnson, AstraZeneca plc |
This chapter will help you gain GLOBAL Market Analysis of Immunotherapy. Further deep in this chapter, you will be able to review Global Immunotherapy Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Immunotherapy Revenue Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Immunotherapy Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Immunotherapy Revenue Market Size By Region
-
-
1.3 Global Immunotherapy Market Size By Drug Type 2019 -2031
-
1.3.1 Monoclonal Antibodies Market Size
-
1.3.2 Immunomodulators Market Size
-
1.3.3 Vaccines Market Size
-
1.3.4 Others Market Size
-
-
1.4 Global Immunotherapy Market Size By Disease 2019 -2031
-
1.4.1 Cancer Market Size
-
1.4.2 Autoimmune Diseases Market Size
-
1.4.3 Infectious Diseases Market Size
-
1.4.4 Others Market Size
-
-
1.5 Global Immunotherapy Market Size By End User 2019 -2031
-
1.5.1 Hospitals Market Size
-
1.5.2 Clinics Market Size
-
1.5.3 Others Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.7.2 Global Market Revenue Split By Drug Type
-
1.7.3 Global Market Revenue Split By Disease
-
1.7.4 Global Market Revenue Split By End User
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
This chapter will help you gain North America Market Analysis of Immunotherapy. Further deep in this chapter, you will be able to review North America Immunotherapy Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
-
2.1 North America Immunotherapy Market Size 2019 - 2031
-
2.1.1 North America Immunotherapy Market Size By Country 2019 - 2031
-
2.1.2 North America Immunotherapy Market Size by Drug Type 2019 -2031
-
2.1.2.1 North America Monoclonal Antibodies Market Size
-
2.1.2.2 North America Immunomodulators Market Size
-
2.1.2.3 North America Vaccines Market Size
-
2.1.2.4 North America Others Market Size
-
-
2.1.3 North America Immunotherapy Market Size by Disease 2019 -2031
-
2.1.3.1 North America Cancer Market Size
-
2.1.3.2 North America Autoimmune Diseases Market Size
-
2.1.3.3 North America Infectious Diseases Market Size
-
2.1.3.4 North America Others Market Size
-
-
2.1.4 North America Immunotherapy Market Size by End User 2019 -2031
-
2.1.4.1 North America Hospitals Market Size
-
2.1.4.2 North America Clinics Market Size
-
2.1.4.3 North America Others Market Size
-
-
This chapter will help you gain Europe Market Analysis of Immunotherapy. Further deep in this chapter, you will be able to review Europe Immunotherapy Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
-
3.1 Europe Immunotherapy Market Size 2019 - 2031
-
3.1.1 Europe Immunotherapy Market Size By Country 2019 - 2031
-
3.1.2 Europe Immunotherapy Market Size by Drug Type 2019 -2031
-
3.1.2.1 Europe Monoclonal Antibodies Market Size
-
3.1.2.2 Europe Immunomodulators Market Size
-
3.1.2.3 Europe Vaccines Market Size
-
3.1.2.4 Europe Others Market Size
-
-
3.1.3 Europe Immunotherapy Market Size by Disease 2019 -2031
-
3.1.3.1 Europe Cancer Market Size
-
3.1.3.2 Europe Autoimmune Diseases Market Size
-
3.1.3.3 Europe Infectious Diseases Market Size
-
3.1.3.4 Europe Others Market Size
-
-
3.1.4 Europe Immunotherapy Market Size by End User 2019 -2031
-
3.1.4.1 Europe Hospitals Market Size
-
3.1.4.2 Europe Clinics Market Size
-
3.1.4.3 Europe Others Market Size
-
-
This chapter will help you gain Asia Pacific Market Analysis of Immunotherapy. Further deep in this chapter, you will be able to review Asia Pacific Immunotherapy Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Immunotherapy Market Size 2019 - 2031
-
4.1.1 Asia Pacific Immunotherapy Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Immunotherapy Market Size by Drug Type 2019 -2031
-
4.1.2.1 Asia Pacific Monoclonal Antibodies Market Size
-
4.1.2.2 Asia Pacific Immunomodulators Market Size
-
4.1.2.3 Asia Pacific Vaccines Market Size
-
4.1.2.4 Asia Pacific Others Market Size
-
-
4.1.3 Asia Pacific Immunotherapy Market Size by Disease 2019 -2031
-
4.1.3.1 Asia Pacific Cancer Market Size
-
4.1.3.2 Asia Pacific Autoimmune Diseases Market Size
-
4.1.3.3 Asia Pacific Infectious Diseases Market Size
-
4.1.3.4 Asia Pacific Others Market Size
-
-
4.1.4 Asia Pacific Immunotherapy Market Size by End User 2019 -2031
-
4.1.4.1 Asia Pacific Hospitals Market Size
-
4.1.4.2 Asia Pacific Clinics Market Size
-
4.1.4.3 Asia Pacific Others Market Size
-
-
This chapter will help you gain South America Market Analysis of Immunotherapy. Further deep in this chapter, you will be able to review South America Immunotherapy Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
-
5.1 South America Immunotherapy Market Size 2019 - 2031
-
5.1.1 South America Immunotherapy Market Size By Country 2019 - 2031
-
5.1.2 South America Immunotherapy Market Size by Drug Type 2019 -2031
-
5.1.2.1 South America Monoclonal Antibodies Market Size
-
5.1.2.2 South America Immunomodulators Market Size
-
5.1.2.3 South America Vaccines Market Size
-
5.1.2.4 South America Others Market Size
-
-
5.1.3 South America Immunotherapy Market Size by Disease 2019 -2031
-
5.1.3.1 South America Cancer Market Size
-
5.1.3.2 South America Autoimmune Diseases Market Size
-
5.1.3.3 South America Infectious Diseases Market Size
-
5.1.3.4 South America Others Market Size
-
-
5.1.4 South America Immunotherapy Market Size by End User 2019 -2031
-
5.1.4.1 South America Hospitals Market Size
-
5.1.4.2 South America Clinics Market Size
-
5.1.4.3 South America Others Market Size
-
-
This chapter will help you gain Middle East and Africa Market Analysis of Immunotherapy. Further deep in this chapter, you will be able to review Middle East and Africa Immunotherapy Market Split by various segments and Country Split.
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Immunotherapy Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Immunotherapy Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Immunotherapy Market Size by Drug Type 2019 -2031
-
6.1.2.1 Middle East and Africa Monoclonal Antibodies Market Size
-
6.1.2.2 Middle East and Africa Immunomodulators Market Size
-
6.1.2.3 Middle East and Africa Vaccines Market Size
-
6.1.2.4 Middle East and Africa Others Market Size
-
-
6.1.3 Middle East and Africa Immunotherapy Market Size by Disease 2019 -2031
-
6.1.3.1 Middle East and Africa Cancer Market Size
-
6.1.3.2 Middle East and Africa Autoimmune Diseases Market Size
-
6.1.3.3 Middle East and Africa Infectious Diseases Market Size
-
6.1.3.4 Middle East and Africa Others Market Size
-
-
6.1.4 Middle East and Africa Immunotherapy Market Size by End User 2019 -2031
-
6.1.4.1 Middle East and Africa Hospitals Market Size
-
6.1.4.2 Middle East and Africa Clinics Market Size
-
6.1.4.3 Middle East and Africa Others Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Immunotherapy Market Size by Drug Type 2019 -2031
-
7.1.2 Country 1Immunotherapy Market Size by Disease 2019 -2031
-
7.1.3 Country 1Immunotherapy Market Size by End User 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
This chapter provides an in-depth analysis of the market share among key competitors of Immunotherapy. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Immunotherapy Market Revenue and Share by Key Players
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Hoffmann-La Roche AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 GlaxoSmithKline
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 AbbVie
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Amgen
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 Merck & Co.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Bristol-Myers Squibb
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Novartis International AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Eli Lilly and Company
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
8.2.12 Johnson & Johnson
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.12.2 Business Overview
-
8.2.12.3 Financials (Subject to data availability)
-
8.2.12.4 Product Types Specification
-
8.2.12.5 Business Strategy
-
8.2.12.6 S.W.O.TAnalysis
-
-
8.2.13 AstraZeneca plc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.13.2 Business Overview
-
8.2.13.3 Financials (Subject to data availability)
-
8.2.13.4 Product Types Specification
-
8.2.13.5 Business Strategy
-
8.2.13.6 S.W.O.TAnalysis
-
-
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Restraints
-
9.3 Market Trends
-
9.4 Market Opportunity
-
9.5 Technological Road Map (Subject to Data Availability)
-
9.6 Product Life Cycle (Subject to Data Availability)
-
9.7 Consumer Preference Analysis
-
9.8 Market Attractiveness Analysis
-
9.9 PESTEL Analysis
-
9.9.1 Political Factors
-
9.9.2 Economic Factors
-
9.9.3 Social Factors
-
9.9.4 Technological Factors
-
9.9.5 Legal Factors
-
9.9.6 Environmental Factors
-
-
9.10 Industrial Chain Analysis (Subject to Data Availability)
-
9.10.1 Industry Chain Analysis
-
9.10.2 Manufacturing Cost Analysis
-
9.10.3 Supply Side Analysis
-
9.10.3.1 Raw Material Analysis
-
9.10.3.2 Raw Material Procurement Analysis
-
9.10.3.3 Raw Material Price Trend Analysis
-
-
-
9.11 Porter’s Five Forces Analysis
-
9.11.1 Bargaining Power of Suppliers
-
9.11.2 Bargaining Power of Buyers
-
9.11.3 Threat of New Entrants
-
9.11.4 Threat of Substitutes
-
9.11.5 Degree of Competition
-
-
9.12 Patent Analysis (Subject to Data Availability)
-
9.13 ESG Analysis
Segmentation Drug Type Analysis 2019 -2031, will provide market size split by Drug Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Drug Type Analysis 2019 -2031
-
10.1 Monoclonal Antibodies
-
10.1.1 Global Immunotherapy Revenue Market Size and Share by Monoclonal Antibodies 2019 -2031
-
-
10.2 Immunomodulators
-
10.2.1 Global Immunotherapy Revenue Market Size and Share by Immunomodulators 2019 -2031
-
-
10.3 Vaccines
-
10.3.1 Global Immunotherapy Revenue Market Size and Share by Vaccines 2019 -2031
-
-
10.4 Others
-
10.4.1 Global Immunotherapy Revenue Market Size and Share by Others 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Disease Analysis 2019 -2031
-
11.1 Cancer
-
11.1.1 Global Immunotherapy Revenue Market Size and Share by Cancer 2019 - 2031
-
-
11.2 Autoimmune Diseases
-
11.2.1 Global Immunotherapy Revenue Market Size and Share by Autoimmune Diseases 2019 - 2031
-
-
11.3 Infectious Diseases
-
11.3.1 Global Immunotherapy Revenue Market Size and Share by Infectious Diseases 2019 - 2031
-
-
11.4 Others
-
11.4.1 Global Immunotherapy Revenue Market Size and Share by Others 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by End User Analysis 2019 -2031
-
12.1 Hospitals
-
12.1.1 Global Immunotherapy Revenue Market Size and Share by Hospitals 2019 -2031
-
-
12.2 Clinics
-
12.2.1 Global Immunotherapy Revenue Market Size and Share by Clinics 2019 -2031
-
-
12.3 Others
-
12.3.1 Global Immunotherapy Revenue Market Size and Share by Others 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Immunotherapy market
Chapter 13 Research Findings
-
13.1 Key Takeaways
-
13.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
13.3 Assumptions and Acronyms
Chapter 14 Customize the Report Edition (Is applicable, On Request, Subject to Data Available, At an Additional Cost)
-
14.1 Segmentation Level Customization
-
14.1.1 Additional Segments and Sub Segment Analysis
-
14.1.2 Cross-split Segments of Immunotherapy
-
14.1.3 Country Level Segment Analysis
-
-
14.2 Global level Data Customization
-
14.2.1 Sales Volume
-
14.2.2 Production
-
14.2.3 Production Capacity
-
14.2.4 Pricing Analysis of Product
-
-
14.3 Region level Data Customization
-
14.3.1 Sales Volume
-
14.3.2 Production
-
14.3.3 Production Capacity
-
14.3.4 Pricing Analysis of Product
-
-
14.4 Country level Data Customization
-
14.4.1 Sales Volume
-
14.4.2 Production
-
14.4.3 Production Capacity
-
14.4.4 Pricing Analysis of Product
-
-
14.5 Company Level Customization
-
14.5.1 Company Sales Volume
-
14.5.2 Company Production Volume
-
14.5.3 Company Production Capacity
-
14.5.4 Company Specific Distributors
-
14.5.5 Manufacturing Process by different manufacturers
-
14.5.6 Global/ Regional/ Country level Major Distributors
-
14.5.7 Additional Competitors Analysis of your choice
-
14.5.8 Tier 1 Company, Tier 2 Company, Tier 3 Company, Start ups
-
14.5.9 Manufacturers Market Concentration Ratio
-
14.5.10 Industry Benchmarking
-
-
14.6 Additional Data Analysis
-
14.6.1 Surveys/polls
-
14.6.2 Value Chain Analysis
-
14.6.3 Raw Material Analysis
-
14.6.4 Price Trend Analysis
-
14.6.5 Supplier/Distributor List
-
14.6.6 Market Economic
-
14.6.7 Supply Demand Gap Analysis
-
14.6.8 Customer Sentiment Analysis
-
14.6.9 Stock Price Prediction Analysis
-
14.6.10 Stock Performance Correlation Analysis
-
14.6.11 Patent Analysis
-
14.6.12 Technology Development Analysis
-
14.6.13 Top Winning Strategies / Strategic Benchmarkeing
-
14.6.14 Heat Map Analysis
-
14.6.15 Marketing Mix Analysis
-
14.6.16 Product Launch Strategy Building
-
-
14.7 Additional Qualitative Data
-
14.7.1 Pipeline Products
-
14.7.2 Industry Events and Developments
-
14.7.3 Sales Key Indicators
-
14.7.4 Risk Analysis
-
14.7.5 Regulatory Landscape
-
14.7.6 Customer Sentiment Analysis
-
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 Immunotherapy Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Immunotherapy Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Immunotherapy Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Immunotherapy Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Immunotherapy Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Immunotherapy Market
Key Questions Answered By Immunotherapy Market Report 2024
| Why Monoclonal Antibodies have a significant impact on Immunotherapy market? |
| What are the key factors affecting the Monoclonal Antibodies and Immunomodulators of Immunotherapy Market? |
| What is the CAGR/Growth Rate of Cancer during the forecast period? |
| By type, which segment accounted for largest share of the global Immunotherapy Market? |
| Which region is expected to dominate the global Immunotherapy Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
